1. Clinical Overview
A fixed-dose combination (FDC) therapy for the symptomatic management of respiratory conditions characterized by productive cough, allergic inflammation, and bronchoconstriction. It synergistically addresses mucus hypersecretion, histamine-mediated allergic symptoms, and leukotriene-mediated airway inflammation. This combination is widely used in India for conditions like allergic bronchitis and cough-variant asthma, offering convenience and improved compliance.
| Onset | Duration | Bioavailability |
|---|---|---|
| Ambroxol: 30 minutes; Levocetirizine: 1 hour; Montelukast: 2-3 hours for bronchoprotection, up to 24 hours for full anti-inflammatory effect. | Ambroxol: 8-12 hours; Levocetirizine: 24 hours; Montelukast: 24 hours. | Ambroxol: ~70-80%; Levocetirizine: >95%; Montelukast: ~64% (fasting). |
2. Mechanism of Action
This combination exerts a triple action: Ambroxol reduces mucus viscosity and promotes clearance, Levocetirizine blocks peripheral H1 receptors inhibiting early-phase allergic response, and Montelukast competitively antagonizes cysteinyl leukotriene type 1 (CysLT1) receptors, inhibiting late-phase allergic inflammation and bronchoconstriction.
3. Indications & Uses
- Symptomatic treatment of Allergic Bronchitis
- Management of Cough associated with Allergic Rhinitis or Asthma
- Symptomatic relief in Allergic Cough
4. Dosage & Administration
Adult Dosage: One tablet (Ambroxol 75mg + Levocetirizine 5mg + Montelukast 10mg) once daily, preferably in the evening. Can be taken with or without food.
Administration: Swallow the tablet whole with a glass of water. Do not crush or chew (unless specified as a chewable tablet). Can be taken at the same time each day, evening dosing may help control nocturnal symptoms and minimize potential daytime drowsiness from levocetirizine.
5. Side Effects
Common side effects may include:
- Headache
- Somnolence (drowsiness)
- Dry mouth
- Fatigue
- Nausea
- Abdominal pain
- Throat irritation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedative effect with levocetirizine. | Major |
| Rifampicin, Phenobarbital, Carbamazepine | Induce CYP enzymes, may reduce montelukast plasma concentration. | Moderate |
| Gemfibrozil | Inhibits CYP2C8, may increase monteluzkast concentration. | Moderate |
| Anticholinergic drugs (Atropine, TCAs) | Additive anticholinergic effects (dry mouth, urinary retention) with levocetirizine. | Moderate |
| Theophylline | Ambroxol may increase theophylline concentration; monitor for toxicity. | Moderate |
7. Patient Counselling
- DO take the medicine as prescribed, usually once daily.
- DO inform your doctor about all other medicines, vitamins, or herbal products you are taking.
- DO report any new or worsening behavioral or mood changes (agitation, depression, suicidal thoughts) immediately.
- DONT consume alcohol while on this medication.
- DONT drive or operate heavy machinery until you know how the medicine affects you.
- DONT use this medicine to treat an acute asthma attack. Use your rescue inhaler (salbutamol) as directed.
8. Toxicology & Storage
Overdose: Expected to reflect individual component toxicity: Severe drowsiness, agitation, restlessness, tachycardia, headache, nausea, vomiting, abdominal pain. In children, montelukast overdose may cause ataxia, thirst, and mydriasis.
Storage: Store below 30°C. Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children. Do not use after the expiry date printed on the pack.